



The Possible Role of Vitamin D in Prevention and Treatment of COVID-19 Disease

Shraga Shany*

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel

***Corresponding author:** Shraga Shany, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, 8410500, Israel, Tel. 972-54-3265020

Abstract

Preliminary studies suggest an inverse link, between serum vitamin D levels and the severity, and mortality in Covid-19 patients. Such patients are suffering from inflammation storm caused by the excess production of cytokines by the immune system. The present review provides indications for the anti-inflammatory activity of 1,25-Dihydroxyvitamin D₃. This vitamin D active metabolite, down-regulates the expression of TNF α in human macrophages. TNF α is a major mediator of host response to pathogens, since it initiates a powerful pro-inflammatory cascade. However, excessive production of TNF α over-activates inflammation accompanied by a cytokines storm, as occurs in the Covid-19 disease. These findings provide a biological basis and possible mode of action by which vitamin D makes its impact on the Covid-19 disease, and emphasize the possible role of vitamin in preventing Covid-19, or at least moderates its severe symptoms. Hence, it is suggested to prevent vitamin D deficiency by vitamin D supplementation for the general population, with a special care for the elderly. In case of acute Covid-19 disease, it is suggested to treat patients with the active metabolite of vitamin D, 1,25(OH)₂D₃, or with its less calcaemic synthetic analogs.

Keywords: COVID-19, Vitamin D, 1,25(OH)₂D₃, Cytokines, TNF α , NF- κ B, Macrophages, respiratory infection

Recent preliminary observations suggest a role for vitamin D in the prevention of Covid-19 disease and mortality [1,2]. Although, no clinical studies on vitamin D supplementation in Covid-19 disease are available, some observations reveal a possible association between vitamin D deficiency and the frequency and severity of the disease [1]. The purpose of the present review is to describe some indications that may provide a biological basis and possible mode of action by which vitamin D makes its impact on the Covid-19 disease.

Patients in second stage of Covid-19 disease, suffer from a severe unregulated inflammation storm caused by the excess production and secretion of cytokines by the immune system. These cytokines include the Tumor Necrosis Factor alpha (TNF α) and a variety of interleukins (IL), including IL-6. Indeed, this is the reason for the experimental therapeutic treatments of Covid-19 patients with steroids, and with IL-6 antibodies (Actemra), in order to moderate this cytokines storm.

In a previous study we have demonstrated in vitro the anti-inflammatory activity of vitamin D in human macrophages [3]. It was shown on this study that the active metabolite of vitamin D, namely 1,25-Dihydroxyvitamin

D₃ (1,25(OH)₂D₃) downregulates the expression of TNF α in human macrophages. TNF α is a major mediator of host response to pathogens since it initiates a powerful pro-inflammatory cascade. However, excessive production of TNF α leads to over-activated inflammation accompanied by a cytokines storm, as occurs in the Covid-19 disease. In a following study we have exposed the mechanism by which 1,25(OH)₂D₃ downregulates the TNF α expression [4]. Transcriptional activation of the TNF α gene in macrophages is dependent on the transcriptional factor NF- κ B. In the resting situation NF- κ B bound to its inhibitor I κ B, remains in the cell cytoplasm. Following pathogens invasion, or polysaccharide activation, I κ B is degraded, and the free NF- κ B is trans-located to the cell nucleus and activates the transcription of specific genes responsible for the immune and inflammatory responses. It was found by us that 1,25(OH)₂D₃, as well as its less calcaemic vitamin D₂ analog (1,24(OH)₂D₂), inhibit the degradation of I κ B. As a result, the translocation of the NF- κ B to the nucleus is decreased, TNF α expression is reduced, and the inflammation became moderated [4]. Moreover, earlier studies have demonstrated that the active metabolite of vitamin D, 1,25(OH)₂D₃, is produced not only in the kidney, but also by human peritoneal

Citation: Shany S (2020) The Possible Role of Vitamin D in Prevention and Treatment of COVID-19 Disease. CasesMed Res J 2(1): 4-6.

Copyright: © 2020 Shany S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: May 19, 2020; **Accepted:** June 15, 2020; **Published:** June 16, 2020

macrophages [3,5] and by human alveolar macrophages [6]. It means that in this case there is an autocrine effect. The $1,25(\text{OH})_2\text{D}_3$ which is produced in the macrophage regulates the $\text{TNF}\alpha$ expression in the same cell. The regulation of cytokines expression by $1,25(\text{OH})_2\text{D}_3$ is not limited to $\text{TNF}\alpha$. Similar down-regulation effect was described for IL-12 in human monocytes [7].

Although there are no direct clinical experiments concerning the effect of vitamin D on the regulation of cytokines production in general, and no such direct experiments in the case of Covid-19, there is a significant number of reports about the positive effect of vitamin D in the treatment of acute respiratory tract infections [8,9] which is the main complication of the Covid-19 disease. This phenomenon is summarized in an extensive meta-analysis of 25 randomized, double blind, placebo controlled trials with a total of 11,321 participants, supplemented by vitamin D [10]. The authors, A.R. Martineau, *et al.* [10], emphasize that vitamin D supplementation was safe, and reduced the risk of acute respiratory tract infection among all participants. However, patients with a deep vitamin D deficiency before intervention, got the most significant benefit by the vitamin D supplementation. We believe that our *in vitro* results concerning the downregulation of cytokines expression in human macrophages by the active metabolite of vitamin D provides the biological and physiological basis for the clinical findings described above. Moreover, we do believe that our results open the gate for the possible treatment of Covid-19 patients with vitamin D, with its metabolites, or with its analogs.

No doubt that in the present Covid-19 disease situation, there is a reduction in the serum vitamin D levels. Home quarantines and the limitations of movements outside, decrease significantly exposure to sunshine. As a result, there is a reduction in the endogenous production of vitamin D. The situation is more serious among the elderly population, specifically those who live in elderly houses. In general, old people are less exposed to sunshine, their endogenous production is decreased with age, and their intestine ability to absorb vitamin D from their diet is also reduced. Even residing in a sunny area, does not guarantee adequate vitamin D levels, as people avoid sunshine in order to prevent skin cancer, or use U.V. protective creams for the same purpose. It is possible of course, and desirable to correct, and normalized, vitamin D levels by vitamin D supplementations. This conclusion is particularly important today with the global spread of the Covid-19 pandemic.

This was concluded also by Dr. Umhau from NIH in a short review that was published on last March 2020 [2]. On this review, Dr. Umhau emphasizes the point that the sunshine deficiency during the winter months increases

the frequency of respiratory tract infections. In light of this situation, obese, or elderly people, as well as people with dark skin should be supplemented with significant amounts of vitamin D in order to get protection against respiratory tract viral infections. As we know, respiratory tract infections is the main complication of Covid-19 disease, and correction of serum vitamin D levels may prevent or decrease the risk of this disease.

It is well known that the severity of the Covid-19 disease is different in various patients. There are patients that pass the disease with light symptoms, while others are experiencing very serious symptoms. It will not come as a surprise for me if it will be found out that some of the seriously ill patients have a vitamin D deficiency status. Moreover, most of the Covid-19 patients and specifically most of the mortality are concentrated in the elderly population. As established already in the literature and in practice, this population suffers from vitamin D deficiency. This is of course not the only reason for this phenomenon, but in light to the above indications, vitamin D deficiency at least contributes to this serious situation. In order to clarify this point, it should be advisable to perform dedicated studies concerning vitamin D serum levels in Covid-19 patients with different degree of disease severity.

In conclusion, it is suggested to prevent vitamin D deficiency by vitamin D supplementation and to keep the normal serum vitamin D levels in the general population, with a special care of the elderly, the obese, and people with dark skin, in order to prevent, or to reduce, at least, the serious symptoms of the Covid-19 disease. It should be remembered that vitamin D has more known advantages in keeping body minerals homeostasis, prevention of bone diseases such as rickets and osteoporosis. Recent data suggest that vitamin D has more recognized activities, such as its anti-carcinogenic activity, as well as its effects on the immune system, as described above. So, it is important to keep the correct serum vitamin D level, anyway.

In case of acute Covid-19 disease a different strategy is suggested. It is known very well that vitamin D is an inert material, and that it should be metabolized in the liver and in the kidney to become the active metabolite $1,25(\text{OH})_2\text{D}_3$. Hence, vitamin D supplementation will not be enough. First of all the production of $1,25(\text{OH})_2\text{D}_3$ in the kidney is highly regulated and its limited endogenous production will not be sufficient for reducing the cytokines storm. Beside this, there are clinical reports about possible damage to the kidney during Covid-19 disease. Such a damage will reduce further the $1,25(\text{OH})_2\text{D}_3$ level. Due to these limitations, it makes sense to treat acute Covid-19 patients with the active metabolite $1,25(\text{OH})_2\text{D}_3$, or with its synthetic analog 1α -Hydroxyvitamin D_3 . However, such

a treatment should be carried out carefully in order to prevent hypercalcaemia. Another alternative treatment in this case, is the use of less calcaemic analogs of the active metabolite of vitamin D.

No doubt that more clinical trials are required in order to shed a light on the role of vitamin D in prevention and treatment of the Covid-19 disease.

This article is not funded, and the Author has no conflicts of interest to declare.

References

1. PC Llie, S Stefanescu, L Smith (2020) The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Infectious Diseases*.
2. JC Umahau (2020) Casting Sunlight on an Epidemic - Is vitamin D a critical host factor to prevent COVID-19? *Medpage Today*.
3. M Cohen-Lahav, A Douvdevani, C Chaimovitz, S Shany (2001) Regulation of TNF- α by 1 α ,25-dihydroxyvitamin D₃ in Human Macrophages from CAPD Patients. *Kidney Intl* 59: 69-75.
4. M Cohen-Lahav, S Shany, C Chaimovitz, D Tubbin, A Douvdevani (2006) Vitamin D decreased NFB activity by increasing IB levels. *Nephrol Dial and Transplant* 21: 889-897.
5. S Shany, J Rapoport, I Zuili, A Gavriel, N Lavi, C Chaimovitz (1991) Metabolism of 25-OH-Vitamin D₃ by peritoneal macrophages from CAPD patients. *Kidney Intl* 39: 1005-1011.
6. JS Adams, MA Gacad (1985) Characterization of 1 alpha hydroxylation of vitamin D₃ sterols by cultured alveolar macrophages from patients with sarcoidosis. *J Exp Med* 161: 755-765.
7. P Gynther, S Toropainen, JM Matilainen, S Seuter, C Carkberg, S Vaisanen (2011) Mechanism of 1 α ,25-dihydroxyvitamin D₃-dependent repression of interleukin-12B. *BBA* 1813: 810-818.
8. RCA Dancer, D Parekh, S Lax (2015) Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). *Thorax* 70: 617-624.
9. AA Ginde, JM Mansbach, CA Jr Camargo (2009) Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 169: 384-390.
10. AR Martineau, DA Jolliffe, RL Hooper (2017) Vitamin D supplementation to prevent acute respiratory tract infections. Systematic review and meta-analysis of individual participant data. *BMJ* 356.